Mark Breidenbach analyst

Currently out of the existing stock ratings of Mark Breidenbach, 123 are a BUY (99.19%), 1 are a HOLD (0.81%).

Mark Breidenbach

Work Performance Price Targets & Ratings Chart

Analyst Mark Breidenbach works with a stock forecast success ratio of 36.71% fulfilled within 184.64 days on average. Previously, Mark Breidenbach worked at OPPENHEIMER.

Mark Breidenbach’s has documented 240 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on EPIX, ESSA Pharma at 13-Dec-2023.

Wall Street Analyst Mark Breidenbach

Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) at 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%) receiving and performance score of 46.29.

Average potential price target upside

ALLO Allogene Therapeutics ARVN Arvinas BLUE Bluebird bio CRBU Caribou Biosciences EPIX ESSA Pharma GBT Global Blood Therapeutics GMDA Gamida Cell Ltd IOVA Iovance Biotherapeutics MBIO Mustang Bio MCRB Seres Therapeutics SYBX Synlogic CGEN Compugen FMTX Forma Therapeutics Holdings IMRX Immuneering Corp ALPN Alpine Immune Sciences KDMN Kadmon Holdings SYRS Syros Pharmaceuticals ACHL Achilles Therapeutics PLC ADR CUE Cue Biopharma FTSV Forty Seven NRIX Nurix Therapeutics  BLRX BioLineRx Ltd

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

8

$3.54 (79.37%)

9

1 months 1 days ago

0/3 (0%)

$2.86 (55.64%)

Buy

10

$5.54 (124.22%)

12

2 months 9 days ago

1/7 (14.29%)

$6.91 (223.62%)

28

Buy

10

$5.54 (124.22%)

12

2 months 9 days ago

0/5 (0%)

$6.91 (223.62%)

Buy

18

2 months 20 days ago

2/9 (22.22%)

$12.2 (210.34%)

94

Hold

35

2 months 23 days ago

1/2 (50%)

$19.71 (128.91%)

6

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Mark Breidenbach is most bullish on?

Potential upside of $8.44 has been obtained for EPIX (ESSA PHARMA)

What Year was the first public recommendation made by Mark Breidenbach?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?